Hiroshi Takata

List of Publications by Year
in descending order

30 papers	1,896 citations	430442 18 h-index	454577 30 g-index
30 all docs	30 docs citations	30 times ranked	3899 citing authors

#	Article	IF	Citations
1	Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nature Medicine, 2018, 24, 923-926.	15.2	263
2	InÂVivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a â€œBlock-and-Lockâ€•Strategy for HIV-1 Treatment. Cell Reports, 2017, 21, 600-611.	2.9	189
3	Transcription factor Foxp1 exerts essential cell-intrinsic regulation of the quiescence of naive T cells. Nature Immunology, 2011, 12, 544-550.	7.0	160
4	Cutting Edge: Phenotypic Characterization and Differentiation of Human CD8+ T Cells Producing IL-17. Journal of Immunology, 2009, 182, 1794-1798.	0.4	153
5	Three Memory Subsets of Human CD8+T Cells Differently Expressing Three Cytolytic Effector Molecules. Journal of Immunology, 2006, 177, 4330-4340.	0.4	147
6	Phenotypic classification of human CD4+ T cell subsets and their differentiation. International Immunology, 2008, 20, 1189-1199.	1.8	121
7	The transcription factor Foxp1 is a critical negative regulator of the differentiation of follicular helper T cells. Nature Immunology, 2014, 15, 667-675.	7.0	107
8	Phenotypic classification of human CD8+ Tâ€„cells reflecting their function: inverse correlation between quantitative expression of CD27 and cytotoxic effector function. European Journal of Immunology, 2004, 34, 999-1010.	1.6	96
9	Delayed differentiation of potent effector CD8 ⁺ T cells reducing viremia and reservoir seeding in acute HIV infection. Science Translational Medicine, 2017, 9, .	5.8	95
10	Programmed Death-1 Is a Marker for Abnormal Distribution of Naive/Memory T Cell Subsets in HIV-1 Infection. Journal of Immunology, 2013, 191, 2194-2204.	0.4	81
11	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV,the, 2019, 6, e297-e306.	2.1	73
12	Cutting Edge: Expression of Chemokine Receptor CXCR1 on Human Effector CD8+ T Cells. Journal of Immunology, 2004, 173, 2231-2235.	0.4	70
13	Functional expression of chemokine receptor CCR6 on human effector memory CD8+ T cells. European Journal of Immunology, 2007, 37, 54-65.	1.6	52
14	Down-regulation of CXCR4 expression on human CD8+ T?cells during peripheral differentiation. European Journal of Immunology, 2004, 34, 3370-3378.	1.6	42
15	Altered Memory Circulating T Follicular Helper-B Cell Interaction in Early Acute HIV Infection. PLoS Pathogens, 2016, 12, e1005777.	2.1	37
16	High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 108-117.	0.9	31
17	Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption. Journal of Clinical Investigation, 2020, 130, 2845-2858.	3.9	31
18	Functional and phenotypic analysis of human memory CD8+ T cells expressing CXCR3. Journal of Leukocyte Biology, 2006, 80, 320-329.	1.5	25

#	Article	IF	Citations
19	Functional heterogeneity of human effector CD8+ T cells. Blood, 2012, 119, 1390-1398.	0.6	18
20	SRSF1 RNA Recognition Motifs Are Strong Inhibitors of HIV-1 Replication. Journal of Virology, 2015, 89, 6275-6286.	1.5	17
21	Failure of Effector Function of Human CD8+ T Cells in NOD/SCID/JAK3âˆ’/âˆ’ Immunodeficient Mice Transplanted with Human CD34+ Hematopoietic Stem Cells. PLoS ONE, 2010, 5, e13109.	1.1	14
22	Comparison of CD4+ T-cell subset distribution in chronically infected HIV+ patients with various CD4 nadir counts. Microbes and Infection, 2010, 12, 374-381.	1.0	12
23	DifferentIn VivoEffects of HIV-1 Immunodominant Epitope-Specific Cytotoxic T Lymphocytes on Selection of Escape Mutant Viruses. Journal of Virology, 2010, 84, 5508-5519.	1.5	12
24	The ingenol-based protein kinase C agonist GSK445A is a potent inducer of HIV and SIV RNA transcription. PLoS Pathogens, 2022, 18, e1010245.	2.1	11
25	Patterns of Cytokine Production in Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Human CD8 + T Cells after Stimulation with HIV-1-Infected CD4 + T Cells. Journal of Virology, 2005, 79, 12536-12543.	1.5	10
26	Modeling HIV-1 Latency Using Primary CD4⁺T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy. Journal of Virology, 2019, 93, .	1.5	9
27	Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. Journal of Clinical Investigation, 2022, 132, .	3.9	9
28	CTL Clonotypes with Higher TCR Affinity Have Better Ability to Reduce the HIV Latent Reservoir. Journal of Immunology, 2020, 205, 699-707.	0.4	7
29	Activation of the Anti-Oxidative Stress Response Reactivates Latent HIV-1 Through the Mitochondrial Antiviral Signaling Protein Isoform MiniMAVS. Frontiers in Immunology, 2021, 12, 682182.	2.2	3
30	Transforming dysfunctional CD8+ T cells into natural controllerâ€“like CD8+ T cells: can TCF-1 be the magic wand?. Journal of Clinical Investigation, 2022, 132, .	3.9	1